Cite
Borelli B, Moretto R, Lonardi S, et al. TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable . ESMO Open. 2018;3(4):e000403doi: 10.1136/esmoopen-2018-000403.
Borelli, B., Moretto, R., Lonardi, S., Bonetti, A., Antoniotti, C., Pietrantonio, F., Masi, G., Burgio, V., Marmorino, F., Salvatore, L., Rossini, D., Zaniboni, A., Zucchelli, G., Martignetti, A., Di Battista, M., Pella, N., Passardi, A., Boccaccino, A., Leone, F., Colombo, C., Granetto, C., Vannini, F., Marsico, V. A., Martinelli, E., Antonuzzo, L., Vitello, S., Delliponti, L., Boni, L., Cremolini, C., & Falcone, A. (2018). TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable . ESMO open, 3(4), e000403. https://doi.org/10.1136/esmoopen-2018-000403
Borelli, Beatrice, et al. "TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable ." ESMO open vol. 3,4 (2018): e000403. doi: https://doi.org/10.1136/esmoopen-2018-000403
Borelli B, Moretto R, Lonardi S, Bonetti A, Antoniotti C, Pietrantonio F, Masi G, Burgio V, Marmorino F, Salvatore L, Rossini D, Zaniboni A, Zucchelli G, Martignetti A, Di Battista M, Pella N, Passardi A, Boccaccino A, Leone F, Colombo C, Granetto C, Vannini F, Marsico VA, Martinelli E, Antonuzzo L, Vitello S, Delliponti L, Boni L, Cremolini C, Falcone A. TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable . ESMO Open. 2018 Jul 09;3(4):e000403. doi: 10.1136/esmoopen-2018-000403. eCollection 2018. PMID: 30018814; PMCID: PMC6045747.
Copy
Download .nbib